Enliven Therapeutics, Inc. (ELVN) Insider Trading
Over the last 3 months, ELVN insiders made 0 open-market buys and 32 sales, a net sale of -$63.8M (SEC Form 4). Over the last 6 months, 151 institutions increased and 86 reduced their position (13F).
Insider Activity
Sentiment
0/100
Buys (3m)
0
Sells (3m)
32
Net (3m)
-$63.8M
Insider trades by month Buys Sells
Mar
Apr
May
Jun
Jul
Aug
Context3-month price +51.8%Institutions accumulating (13F)
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| Aug 19, 2026 | Hohl Benjaminofficer: CHIEF FINANCIAL OFFICER | Sell | 1,388 | $59.35 |
| Aug 19, 2026 | Collins Helen Louiseofficer: CHIEF MEDICAL OFFICER | Sell | 3,900 | $58.37 |
| Aug 19, 2026 | Collins Helen Louiseofficer: CHIEF MEDICAL OFFICER | Option | 5,000 | $2.48 |
| Aug 19, 2026 | Collins Helen Louiseofficer: CHIEF MEDICAL OFFICER | Sell | 1,100 | $59.35 |
| Aug 19, 2026 | Hohl Benjaminofficer: CHIEF FINANCIAL OFFICER | Sell | 4,630 | $58.35 |
| Aug 6, 2026 | Derynck Mika Kdirector | Option | 23,364 | $14.85 |
| Aug 6, 2026 | Derynck Mika Kdirector | Sell | 158,795 | $60.21 |
| Aug 6, 2026 | Derynck Mika Kdirector | Option | 87,373 | $2.48 |
| Aug 6, 2026 | Derynck Mika Kdirector | Option | 20,491 | $22.47 |
| Aug 6, 2026 | Derynck Mika Kdirector | Option | 27,567 | $25.28 |
| Jul 21, 2026 | Collins Helen Louiseofficer: CHIEF MEDICAL OFFICER | Sell | 231 | $50.05 |
| Jul 21, 2026 | Hohl Benjaminofficer: CHIEF FINANCIAL OFFICER | Sell | 369 | $51.48 |
| Jul 21, 2026 | Collins Helen Louiseofficer: CHIEF MEDICAL OFFICER | Sell | 459 | $51.55 |
| Jul 21, 2026 | Collins Helen Louiseofficer: CHIEF MEDICAL OFFICER | Option | 5,000 | $2.48 |
| Jul 21, 2026 | Hohl Benjaminofficer: CHIEF FINANCIAL OFFICER | Sell | 2,638 | $53.38 |
| Jul 21, 2026 | Collins Helen Louiseofficer: CHIEF MEDICAL OFFICER | Sell | 2,184 | $53.42 |
| Jul 21, 2026 | Collins Helen Louiseofficer: CHIEF MEDICAL OFFICER | Sell | 63 | $53.92 |
| Jul 21, 2026 | Hohl Benjaminofficer: CHIEF FINANCIAL OFFICER | Sell | 2,564 | $52.32 |
| Jul 21, 2026 | Collins Helen Louiseofficer: CHIEF MEDICAL OFFICER | Sell | 2,063 | $52.39 |
| Jul 21, 2026 | Hohl Benjaminofficer: CHIEF FINANCIAL OFFICER | Option | 1,072 | $2.48 |
| Jul 21, 2026 | Hohl Benjaminofficer: CHIEF FINANCIAL OFFICER | Sell | 123 | $53.87 |
| Jul 21, 2026 | Hohl Benjaminofficer: CHIEF FINANCIAL OFFICER | Sell | 324 | $49.97 |
| Jul 8, 2026 | Kunkel Lori Annedirector | Sell | 5,889 | $50.84 |
| Jul 8, 2026 | Kunkel Lori Annedirector | Sell | 4,111 | $49.98 |
| Jun 24, 2026 | ORBIMED ADVISORS LLC10 percent owner | Sell | 787,024 | $45.38 |
| Jun 24, 2026 | ORBIMED ADVISORS LLC10 percent owner | Sell | 46,776 | $45.00 |
| Jun 24, 2026 | ORBIMED ADVISORS LLC10 percent owner | Sell | 24,846 | $45.38 |
| Jun 24, 2026 | ORBIMED ADVISORS LLC10 percent owner | Sell | 1,477 | $45.00 |
| Jun 22, 2026 | Hohl Benjaminofficer: CHIEF FINANCIAL OFFICER | Sell | 1,238 | $44.75 |
| Jun 22, 2026 | Collins Helen Louiseofficer: CHIEF MEDICAL OFFICER | Sell | 1,268 | $42.83 |
Source: ELVN SEC Form 4 filings, latest Aug 19, 2026. For informational purposes only — not investment advice.
Institutional activity (13F)
How institutions changed their ELVN positions over the last 6 months (SEC Form 13F).
Increased
151
New positions
129
Reduced
86
Sold out
18
Largest moves
| Institution | Action | Shares | Filed |
|---|---|---|---|
| FMR LLC | Increased | 10.0M | Aug 13, 2026 |
| ORBIMED ADVISORS LLC | Unchanged | 8.0M | May 15, 2026 |
| FMR LLC | Reduced | 6.8M | May 15, 2026 |
| ORBIMED ADVISORS LLC | Reduced | 6.8M | Aug 14, 2026 |
| Polar Capital Holdings Plc | Increased | 6.4M | Aug 14, 2026 |
| POLAR CAPITAL HOLDINGS PLC | Increased | 5.1M | May 15, 2026 |
| BlackRock, Inc. | Increased | 4.4M | Aug 7, 2026 |
| Vestal Point Capital, LP | Increased | 4.0M | Aug 14, 2026 |
| BLACKROCK, INC. | Increased | 3.7M | May 13, 2026 |
| Commodore Capital LP | Unchanged | 3.3M | Aug 14, 2026 |
| COMMODORE CAPITAL LP | Reduced | 3.3M | May 15, 2026 |
| VESTAL POINT CAPITAL, LP | Reduced | 3.3M | May 15, 2026 |
| PRICE T ROWE ASSOCIATES INC /MD/ | Increased | 2.9M | Aug 14, 2026 |
| VANGUARD CAPITAL MANAGEMENT LLC | Increased | 2.6M | Aug 13, 2026 |
| BELLEVUE GROUP AG | New Position | 2.3M | May 15, 2026 |
Source: SEC Form 13F filings. For informational purposes only — not investment advice.